# High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28

Source: https://onco.cc/trials/nct03329183/  
OnCo record `nct03329183` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of UGT1A1 genotyping before irinotecan in Colorectal cancer, run by Shanghai Changzheng Hospital, with a status the registry has not verified recently.

## Summary

High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28 is a phase 2 interventional study registered as NCT03329183 by Shanghai Changzheng Hospital, with 90 participants planned, started 2019-03 and due to reach its primary completion in 2019-03. Interventions recorded: Irinotecan. Conditions recorded: Colorectal Cancer.

Linked to the technology UGT1A1 genotyping before irinotecan because the registry's title names it ("ugt1a1 6") and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03329183
- Phase: 2
- Setting: High-dose FOLFIRI Versus Standard-dose FOLFIRI or FOLFOX-6 in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28: A Randomized, Opened, Phase II Clinical Trial
- Sponsor: Shanghai Changzheng Hospital
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT03329183: https://clinicaltrials.gov/study/NCT03329183

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- technologies: [UGT1A1 genotyping before irinotecan](https://onco.cc/technologies/ugt1a1-genotyping/)
- drugs: [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/)

---
JSON: https://onco.cc/api/v1/entities/nct03329183.json